Global Health Matters

6 June 2017 - By
The most indisputable of all facts on global health is that we’re living longer and healthier lives than ever, and in an era of continuous health improvement. What were once considered life-threatening diseases are now manageable conditions, and not just for patients, but for our health systems also. Where Hepatitis ...
Read More
2 June 2017 - By Thomas B. Cueni
In January 2016, more than 100 companies and industry associations had signed a Declaration on Combatting Antimicrobial Resistance at the World Economic Forum in Davos, followed by a Roadmap of several big pharma at the UN High-Level Meeting in September 2016 – a common framework of principles for global measures to curb the development of antibiotic resistance. ...
Read More
29 May 2017 - By Thomas B. Cueni
Thinking about how to be a healthy older person is like thinking about glaciers crashing into Arctic seas as a result of climate change. Too far away to imagine, and we’ll worry when the effects reach our doorsteps. In reality, the challenge is here today asking all of us, at ...
Read More
24 May 2017 - By Cyntia Genolet
As falsified medicines are debated this week at the World Health Assembly, IFPMA shares what the biopharmaceutical is doing to combat this risk to individual and public health.    If there’s one place not to take a gamble, it’s on whether or not a medicine is real or falsified. Yet ...
Read More
20 May 2017 - By Thomas B. Cueni
  I must admit I had been somewhat skeptical about the "WHO Fair Pricing Forum" held last week in Amsterdam. There were multiple reasons for my apprehension. One concern was clearly that the notion of “fair” is pretty much in the eye of the beholder, another was that none of ...
Read More
27 April 2017 - By Thomas B. Cueni
Over the course of my lifetime, human lifespan extended by three decades.  Today we hope to lead healthy lives well into our 80s. Now I have to declare a vested interest in this topic:  I am an aspiring role model for active and healthy ageing (I’m past 60 and look ...
Read More
25 April 2017 - By Thomas B. Cueni
As we look forward to hosting the Geneva Pharma Forum during current World Immunization Week, finding solutions to pre-empt or mitigate vaccine shortages is top-of-mind here at IFPMA and for our members. What’s more, recently the first Access to Vaccines Index (ATVI) was published – a set of report cards ...
Read More
21 April 2017 - By Thomas B. Cueni
After 30 years in the world of policymaking and business, there is not much that can faze me; but it is fair to say that nothing could have prepared me for meeting Agnes. This has been a week when Geneva played host to ministers, scientists, WHO officials, philanthropists and business ...
Read More
Angkor Thom. Siem Reap Cambodia
7 April 2017 - By Thomas B. Cueni
The name Kantha Bopha is well known in Switzerland. Beat Richner, pediatrician, cello player, and savvy fundraiser, has been working there tirelessly for over 20 years on his life-long project. He had already worked at the Children's Hospital in Phnom Penh in the early 70’s, then the terror of the ...
Read More
4 April 2017 - By Thomas B. Cueni
Animal testing has been and will remain controversial. Whereas most people accept the need to test new medicines or vaccines on laboratory animals before they are authorized for human use, it is also widely accepted that there is a need to strike the right and careful balance between expected benefit ...
Read More
20 March 2017 - By Thomas B. Cueni
It is quite amazing how health policy discussions are often held in a distorted and simplified manner. Nowhere does this apply more than in discussions on drugs and the pharmaceutical industry. Although a large portion of public health spending is accounted for by hospitals, doctors, other health care personnel, and ...
Read More
16 March 2017 - By Thomas B. Cueni
(This is a re-posting that was first published on Monday 13 March in the Basler Zeitung) ‘Vets are expensive. Antibiotics are cheap.’ In a nutshell, this was a quote extracted from last week’s BBC report of the growing global problem of antimicrobial resistance highlighting the plight of overuse of antibiotics on ...
Read More
9 March 2017 - By Thomas B. Cueni
Costs of cancer drugs have risen significantly in Switzerland over the past ten years, from an estimated CHF 445 million to CHF 775 million at ex-factory prices. Bearing in mind future combination treatments in immune-oncology, treatments which are likely to bring from now on unhoped for outcomes, it is timely ...
Read More
27 February 2017 - By Thomas B. Cueni
We need an informed societal debate on how much prolonging life should be allowed to cost (Note to our readers: This is a re-posting that was first published on Monday 27 February in the Basler Zeitung) Recently, the Secretary of Health for the Swiss canton of Zurich, Thomas Heiniger, called for ...
Read More
3 February 2017 - By Laetitia Bigger
In the wake of WEF Davos, there is consensus more than ever that the private sector has a role to play in achieving the 2030 Sustainable Development Goals. From investment opportunities to research capabilities, collective ambitions to sharing information, many sectors see the value of coalitions and opportunities for the ...
Read More